Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Chinese-German Journal of Clinical Oncology
Metadata
Title
Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma: the experience of a single institution of Guangzhou in the beginning of the 21st century
Authors
Xiaoqing Liu
Wei Luo
Mengzhong Liu
Ling Ye
Ying Sun
Yunfei Xia
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
The Chinese-German Journal of Clinical Oncology / Issue 4/2008
Print ISSN: 1610-1979
Electronic ISSN: 1613-9089
DOI
https://doi.org/10.1007/s10330-007-0177-2

Other articles of this Issue 4/2008

The Chinese-German Journal of Clinical Oncology 4/2008 Go to the issue

OriginalPaper

Hypermethylation of promoter 5′CpG island of p16 gene in glioma tissue and plasma

OriginalPaper

Comparison of efficacy and toxicity between gemcitabine plus cisplatin and plus carboplatin in first-line treatment of advanced non-small cell lung cancer

OriginalPaper

Effect of matrine on HepG2 cells: role of glutathione and cytochrome c

OriginalPaper

The clinical evaluation of Iressa first-line treatment of senium advanced-stage non-small cell lung cancer

OriginalPaper

Expressions of FEZ1 and Survivin, and their significance in small cell lung cancer and squamous cell lung carcinoma

OriginalPaper

Efficacy and nursing of stereotactic radiotherapy in lung cancer patients with brain metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits